Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report released on Friday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB stock opened at $0.00 on Friday. The stock has a market capitalization of $100,084.00, a PE ratio of -0.02 and a beta of […]
23 Sep 07:08 · The Markets Daily